Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Shenandoah Oncology P.C
mi
from
Winchester, VA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Shenandoah Oncology P.C
mi
from
Winchester, VA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Washington
mi
from
Seattle, WA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
PeaceHealth United General Medical Center
mi
from
Sedro-Woolley, WA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
PeaceHealth United General Medical Center
mi
from
Sedro-Woolley, WA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wheeling Hospital/Schiffler Cancer Center
mi
from
Wheeling, WV
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wheeling Hospital/Schiffler Cancer Center
mi
from
Wheeling, WV
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Agnes Hospital/Agnesian Cancer Center
mi
from
Fond Du Lac, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Agnes Hospital/Agnesian Cancer Center
mi
from
Fond Du Lac, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center
mi
from
Marshfield, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center
mi
from
Marshfield, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wheaton Franciscan Cancer Care - All Saints
mi
from
Racine, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wheaton Franciscan Cancer Care - All Saints
mi
from
Racine, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Rhinelander, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Rhinelander, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Michael's Hospital
mi
from
Stevens Point, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Michael's Hospital
mi
from
Stevens Point, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Northwell Health- Center for Advanced Medicine
mi
from
Lake Success, NY
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Texas Oncology - Fort Worth Cancer Center
mi
from
Fort Worth, TX
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Texas Oncology - Fort Worth Cancer Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Beaumont Hospital - Farmington Hills
mi
from
Farmington Hills, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Beaumont Hospital - Farmington Hills
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Virginia University Charleston Division
mi
from
Charleston, WV
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Geisinger Cancer Services-Pottsville
mi
from
Pottsville, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
HSHS Sacred Heart Hospital
mi
from
Eau Claire, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
HSHS Sacred Heart Hospital
mi
from
Eau Claire, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Peter's Health Partners
mi
from
Albany, NY
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Peter's Health Partners
mi
from
Albany, NY
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Camden Clark Medical Center
mi
from
Parkersburg, WV
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
WVUH-Berkely Medical Center
mi
from
Martinsburg, WV
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
WellStar Cobb Hospital
mi
from
Austell, GA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
WellStar Cobb Hospital
mi
from
Austell, GA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Tidelands Georgetown Memorial Hospital
mi
from
Georgetown, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Tidelands Georgetown Memorial Hospital
mi
from
Georgetown, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Centra Lynchburg Hematology Oncology Clinic
mi
from
Lynchburg, VA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Centra Lynchburg Hematology Oncology Clinic
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Kent Hospital
mi
from
Warwick, RI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Kent Hospital
mi
from
Warwick, RI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint John Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Promedica Flower Hospital
mi
from
Sylvania, OH
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Providence Hospitals - Southfield
mi
from
Southfield, MI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Sanford Joe Lueken Cancer Center
mi
from
Bemidji, MN
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Sanford Joe Lueken Cancer Center
mi
from
Bemidji, MN
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Atrium Health Union/LCI-Monroe
mi
from
Monroe, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Atrium Health Union/LCI-Monroe
mi
from
Monroe, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital South
mi
from
Saint Louis, MO
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital South
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Aurora Bay Area Medical Group-Marinette
mi
from
Marinette, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital Cancer Center at Oconto Falls
mi
from
Oconto Falls, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
OptumCare Cancer Care at Fort Apache
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Marshfield
mi
from
Marshfield, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UM Upper Chesapeake Medical Center
mi
from
Bel Air, MD
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UM Upper Chesapeake Medical Center
mi
from
Bel Air, MD
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UM Saint Joseph Medical Center
mi
from
Towson, MD
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UM Saint Joseph Medical Center
mi
from
Towson, MD
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
AdventHealth Infusion Center Asheville
mi
from
Asheville, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Atrium Health Cabarrus/LCI-Concord
mi
from
Concord, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Atrium Health Cabarrus/LCI-Concord
mi
from
Concord, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
AdventHealth Hendersonville
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Atrium Health Cleveland/LCI-Cleveland
mi
from
Shelby, NC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Atrium Health Cleveland/LCI-Cleveland
mi
from
Shelby, NC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Marshfield Medical Center-Rice Lake
mi
from
Rice Lake, WI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Bayhealth Hospital Kent Campus
mi
from
Dover, DE
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Bayhealth Hospital Kent Campus
mi
from
Dover, DE
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
mi
from
Jonesboro, AR
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Regional Cancer Center at Indian Path Community Hospital
mi
from
Kingsport, TN
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ascension Saint Mary's Hospital
mi
from
Saginaw, MI
Click here to add this to my saved trials